Free Trial

Xencor Q2 2023 Earnings Report

Xencor logo
$24.57 +0.44 (+1.82%)
(As of 12/23/2024 05:45 PM ET)

Xencor EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.91
Beat/Miss
Beat by +$0.54
One Year Ago EPS
-$0.57

Xencor Revenue Results

Actual Revenue
$45.52 million
Expected Revenue
$26.25 million
Beat/Miss
Beat by +$19.27 million
YoY Revenue Growth
+50.90%

Xencor Announcement Details

Quarter
Q2 2023
Time
After Market Closes

Conference Call Resources

First JFK… next Elon? (Ad)

Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Xencor Earnings Headlines

Brokerages Set Xencor, Inc. (NASDAQ:XNCR) PT at $36.56
Missed Nvidia? Buy Elon Musk’s “Silent Partner”
In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.
Xencor initiated with an Overweight at Wells Fargo
Xencor’s Promising Pipeline and Strategic Partnerships Drive Buy Rating
See More Xencor Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xencor? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xencor and other key companies, straight to your email.

About Xencor

Xencor (NASDAQ:XNCR), a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

View Xencor Profile

More Earnings Resources from MarketBeat